MUC16 and ovarian cancer: developed a dual-specificity T cell engager-modified oncolytic adenovirus (OAd-MUC16-BiTE) targeting MUC16, activating cytotoxic T cells to effectively overcome the immunosuppressive environment in ovarian cancer and enhance therapeutic efficacy (130).